BioSpace News Archive

Recombinant vaccine is one of the important tools today in healthcare industry.

Phase 1b study shows bispecific antibody amivantamab and third-generation tyrosine kinase inhibitor (TKI) lazertinib achieved a 100 percent overall response rate in treatment-naïve EGFR-mutated NSCLC patient cohort

Participants with advance non-small cell lung cancer and colorectal cancer experienced the greatest benefits in this first-in-human phase 1 clinical trial.

Confirmed and Durable Anticancer Activity in Heavily Pretreated Non-Small Cell Lung Cancer (NSCLC) Patients From Phase 1 Trial

MGD019 well-tolerated with early signals of activity in advanced solid tumors not typically responsive to checkpoint inhibition

In lieu of an in-person update to the media, Dr. Theresa Tam, Canada’s Chief Public Health Officer, issued the following statement

Researchers Share New Data for Vibostolimab (MK-7684), Merck’s Anti-TIGIT Therapy, as Monotherapy and in Combination With KEYTRUDA® (pembrolizumab); First-Time Results for First-in-Class MK-4830 (Anti-ILT4 Therapy); and Late-Breaking Data for MK-6482 (HIF-2α Inhibitor)

LYNPARZA is the only PARP inhibitor to demonstrate overall survival in metastatic castration-resistant prostate cancer

As COVID-19 continues to affect the global populace, the diagnosis of the novel coronavirus for speedy recovery has become the need of the hour.

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, jointly announce with Eli Lilly and Company that biomarker results from the ORIENT-11 study were released in a mini oral presentation at the European Society for Medical Oncology Virtual Congress 2020.